
Stock investments ranging from Biotech, Pharmaceutical, and Medical Devices in the Healthcare Sector. Covering Clinical Trial recommendations and FDA Approvals.
Showing posts with label Obesity Drugs. Show all posts
Showing posts with label Obesity Drugs. Show all posts
7/15/10
Vivus' Qnexa Not Recommended By FDA Advisory Committee

Labels:
Anti-obesity medication,
Clinical trial,
Food and Drug Administration,
Obesity,
Obesity Drugs,
Phentermine/topiramate,
Qnexa,
Vivus
Subscribe to:
Posts (Atom)